MSGMHIGH SIGNALFINANCIAL10-K

MSGM eliminated going-concern language and substantially improved its financial position with notably higher assets, reduced liabilities, and stronger operational performance.

The removal of "substantial doubt regarding our ability to continue as a going concern" represents a dramatic improvement in the company's financial stability assessment. This shift from distressed status to apparent financial health, combined with meaningfully expanded share count and stronger balance sheet metrics, suggests either successful capital raising or significant operational turnaround that materially changes the investment thesis.

Comparing 2026-03-10 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

MSGM demonstrated substantial financial improvement across key metrics, with total assets nearly doubling to $12.0M while current liabilities declined by a third to $3.4M, creating a much stronger balance sheet position. Revenue grew a solid 30% to $11.3M with gross profit expanding meaningfully, while the company reduced R&D expenses and dramatically cut interest expense from $121K to $19K. The overall picture signals a company that has successfully addressed its liquidity concerns and achieved notable operational leverage.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+90.9%
$6.3M$12.0M

Asset base grew 90.9% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
-84.4%
$121K$19K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Gross Profit
P&L
+68.5%
$5.5M$9.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Capital Expenditure
Cash Flow
-51.8%
$25K$12K

Capex reduced 51.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
-47.9%
$3.4M$1.8M

R&D spending cut 47.9% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-33%
$5.0M$3.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Revenue
P&L
+30%
$8.7M$11.3M

Strong top-line growth of 30% — accelerating demand or successful expansion into new markets.

Total Liabilities
Balance Sheet
-13%
$5.0M$4.4M

Liabilities reduced 13% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-20
ADDED
As of March 10, 2026, the registrant had 5,078,450 shares of Class A common stock, with 1 vote per share , and 700,000 shares of Class B common stock, with 10 votes per share, issued and outstanding.
These risks include, but are not limited to, the following principal risks: Risks Related to Our Financial Condition and Liquidity We may require additional capital to meet our financial obligations, and this capital might not be available on acceptable terms or at all.
Restrictions under the Credit Agreement with Citibank may affect our ability to finance our operations.
Risks Related to Our Business and Industry If we do not consistently deliver popular products our business will be negatively impacted.
Our ability to acquire and maintain licenses to intellectual property affects our revenue and profitability.
+7 more — sign up free →
REMOVED
As of March 20, 2025, the registrant had 3,183,558 shares of Class A common stock, with 1 vote per share , and 700,000 shares of Class B common stock, with 10 votes per share, issued and outstanding.
and Technology In Business B.V., the sellers of Studio 397 B.V.
( Studio397 ), relating to our acquisition of 100% of the share capital of Studio397 in April 2021.
These risks include, but are not limited to, the following principal risks: We have incurred significant losses since our inception, and we expect to continue to incur losses for the foreseeable future.
Accordingly, our financial condition raises substantial doubt regarding our ability to continue as a going concern.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →